Cost of Tuberculosis and Multidrug Resistance Tuberculosis Diagnostic tests in Tigray Health Research Institute, Mekelle, Northern Ethiopia
DOI:
https://doi.org/10.20372/ejphn.v7i1.241Keywords:
Cost, tuberculosis, recurrent cost, capital equipment, diagnostic tests, MekelleAbstract
Background: Tuberculosis is a communicable disease, one of the top ten causes of death and the effectiveness, affordability, or budget impact implications of diagnostic tests requires reliable unit cost estimates. Therefore, the present study figured out unit cost of tuberculosis (TB) and multidrug resistance tuberculosis (MDR TB) diagnostic tests by performing detailed cost analysis methods to help decision makers and researchers.
Objective: To estimate the unit cost of tuberculosis and multidrug resistance tuberculosis diagnostic tests.
MethodCross sectional bottom-up and retrospective top-down approaches from health care providers’ perspective were used in the cost estimation process. Inputs were consumables, capital equipment, personnel, and buildings. Capital items were annualized using the equivalent annual cost estimation formula and a 3 percent discount rate. All unit costs were calculated in a purposely built Excel spreadsheet that was developed for tuberculosis diagnostic test costing. Locally collected costs were in Ethiopian birr and were converted to United States dollars using the March 2020 exchange rate.
Results: This study revealed that the unit costs of tuberculosis and multidrug resistance tuberculosis were 6.16 USD for sputum smear fluorescence microscopy, 6.33 USD for Ziehl-Neelsen light smear microscopy, 19.19 USD for GeneXpert, 28.37 USD for first line probe assay, 21.22 USD for second line probe assay, 25.76 USD for solid culture, 20.51 USD for liquid culture per test. Moreover, from all costs of TB and MDR TB diagnostic tests 44.54 USD, 24.81 USD, 49.34 USD, and 8.85 USD per test were consumables, personnel, capital equipment and building respectively.
Conclusion and recommendation
In this study, among all tuberculosis and multidrug resistance tuberculosis tests first line probe assay was the most expensive accompanied by culture, GeneXpert, and sputum smear microscope. Additionally capital equipment and consumables hold a large share of unit costs of all tests.
Downloads
References
Creese A PD (2000). Cost analysis in primary health care: a training manual for programme managers.
EMoH (2022). Ethiopian tuberculosis roadmap overview.
ENHA (2017). Ethiopia’s sixth national health account.
Getnet F, Demissie M, Assefa N, Mengistie B, (2017). Worku A. Delay in diagnosis of pulmonary tuberculosis in low- and middle-income settings: systematic review and meta-analysis. BMC Pulm Med; 17: 202.
Global Drug Facility Tuberculosis diagnosis ordering list, 2018-2019.
Halbwachs H (2007). maintenance and life expectancy of and the life expectancy of health care equipments in developing economics, Health estate.
Kenton W (2019). Corporate of finance and accounting ,equivalent annual cost definition.
Laokri S DM, Weil O, Kafando B, Dembele SM, Dujardin B (2013). Patients Are Paying too Much for Tuberculosis: A Direct Cost-Burden Evaluation in Burkina Faso. PLoS One ;8(2).
LeAnna Cates, V. crudu, A. Codreanu (2020). Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting in Moldova. Journal of tuberculosis and lung disease; 25(3):228–230
Lida Jouca de Assis Figueredo, Silvana Spíndola de Miranda (2020). Cost analysis of smear microscopy and the Xpert assay for tuberculosis diagnosis in Brazil. Journal of the Brazilian Society of Tropical Medicine; 53
MacPherson P, Houben Rm, Glynn JR, Corbett EL, Kranzer K (2014). Loss of follow-up before treatment of tuberculosis patients in low- and middle-income countries and in high-burden countries: a systematic review and meta-analysis. Bull World Health Organ; 92: 126–38.
Pallas SW CM, Hy C, Killam WP, Warren D, Moore B (2018). Cost analysis of tuberculosis diagnosis in Cambodia with and without Xpert® MTB/RIF for people living with HIV/AIDS and people with presumptive multidrug-resistant tuberculosis. Applied health economics and health policy;16(4):537-48
Pantoja A FC, Vassall A, Weyer K, Floyd K (2013). Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. EurRespir; (42):708–20.
Rupert S VA, Raizada N, Khaparde SD, Boehme C, Salhotra VS, Sachdeva KS et al (2017). Bottom-up or top-down: unit cost estimation of tuberculosis diagnostic tests in India. Tuberculosis and Lung Disease;21(4):375-80
Shah M CV, Coetzee G, Churchyard G, Dorman S E (2013). Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug resistant tuberculosis in South Africa. BMC Infect Dis;13(352).
Sohn H MJ, Albert H, Dheda K, Pai M (2009). TB diagnostic tests: how do we figure out their costs? Expert review of anti-infective therapy; 7(6):723-33.
United State Dollar exchange rate in Ethiopia (2020). https://www.exchangerates.org.uk/USD-ETB-spot-exchange-rates-history . Accessed 10 March 2020.
Walker D KL (2002). Allowing for differential timing in cost analyses: discounting and annualization. Health Policy Plannnng;17:112–8.
WHO (2017). World Health Organization. Analysing Health Sector Financing and Expenditure.
WHO (2018).World Health Organization. Global tuberculosis report.
WHO (2020).World Health Organization. Global tuberculosis report.
WHO (2021). World Health Organization. Global tuberculosis report.
WHO (2015).World Health Organization. Scale up TB control initiatives to reach the missing one million cases.
Zuzana Spacirova, David Epstein, Laticia Garcia (2020). General framework for classifing costing methods for economic evaluation of health care. European journal of health economics; 21 (529-542)
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 Ethiopian Journal of Public Health and Nutrition (EJPHN)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under GNU General public license.